Cécile Alanio - Concepedia

Author

Cécile Alanio

Also Known As

Alanio, Cécile, C Alanio, C. Alanio, C. Alanio-Bréchot, Cecile Alanio, Cécile Alanio, Cécile Alanio-Bréchot, Cécile Alanio‐Bréchot

141

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

University of Pennsylvania Translational Therapeutics (United States)Parker Institute for Cancer Immunotherapy Inserm Children's Hospital of Philadelphia

About

Cécile Alanio is an author at University of Pennsylvania specializing in medicine, immunology, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	3.4K
2	Cell Biology	4	4	1K
3	Allergy	2	2	354
4	Engineering	1	1	79
5	Clinical Immunology	1	1	201

Cécile Alanio

Publications

7.1K

Citations

H-Index

Page 1

	Year	Citations
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Divij Mathew, Josephine R. Giles, Amy E. Baxter, Science	2020	1.6K
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells J. Joseph Melenhorst, Gregory M. Chen, Meng Wang, Nature Hematological MalignancyDecade-long Leukaemia RemissionsMalignant Blood DisorderT-regulatory CellImmunology	2022	851
PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer Cécile Badoual, Stéphane Hans, Nathalie Merillon, Cancer Research Neck CancerHpv-associated HeadT-regulatory CellImmunologyCell Death	2012	623
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer Erin M. Bange, Nicholas Han, Paul Wileyto, Nature Medicine	2021	503
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection Elizabeth M. Anderson, Eileen C. Goodwin, Anurag Verma, Cell VaccinationSars-cov-2 InfectionCovid-19 PandemicViral PathogenesisImmunology	2021	404
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial Lacey Padrón, Deena M. Maurer, Mark H. O’Hara, Nature Medicine Randomized Phase 2Pancreatic CancerGastrointestinal OncologyMedicineImmunologic Analyses	2022	316
Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors Étienne Patin, Milena Hasan, Jacob Bergstedt, Nature Immunology InflammationImmunogeneticsAllergyAutoimmune DiseaseNatural Variation	2018	309
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study Mark H. O’Hara, Eileen M. O’Reilly, Gauri R. Varadhachary, The Lancet Oncology Phase 1BPancreatic CancerMetastatic Pancreatic AdenocarcinomaMedicineImmunology	2020	286
Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19 Laura A. Vella, Josephine R. Giles, Amy E. Baxter, Science Immunology Clinical ImmunologyImmunodeficienciesDeep Immune ProfilingImmunologyImmune Regulation	2021	201
Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines Petar Šćepanović, Cécile Alanio, Christian Hammer, Genome Medicine	2018	188

Page 1